Xenetic Biosciences, Inc. (XBIO)

NASDAQ: XBIO · USD

$2.10

+0.28 (+15.1%)· Recorded snapshot

Market cap	4.9M
Revenue (ttm)	3.3M
Net income (ttm)	-2.5M
EPS (ttm)	-$1.19
Shares out	2.3M
Volume	135,553
Beta	2.20

Market data

Price

Recent price action with selectable time range.

Financial snapshot

Revenue (ttm): 3.3M
Net income (ttm): -2.5M
EPS (ttm): -$1.19
Market cap: 4.9M

Ticker	Name	Market cap	P/E	P/S	ROIC	5Y rev CAGR	1Y total return	Rating
EXAS	Exact Sciences Corp	—	—	—	—	—	—	持有

Calendar

Next earnings

Upcoming earnings date and setup when available.

Upcoming

DateLoading

Window—

EPS estimate—

Revenue estimate—

Sector percentile context

Refreshed 2026-10-28 19:55 UTC

Forward P/En/a

P25 13.4P50 20.2P75 35.7

Trailing P/En/a

P25 15.4P50 25.8P75 43.5

ROE-47

P25 -113.8P50 -46.5P75 -0.9

ROIC-31.4

P25 -68.5P50 -27.1P75 1.8

Benchmarks · 1M

All XBIO indicators

Market & fundamental data

Available fields

197

Groups with data

Currency

USD

Showing 197 of 197 available metrics for this ticker.

Profile and market data

Ticker identity, listing, currency, market cap, and source dates.

Metric	Value
Amount currency	USD
CIK code	0001534525
Company name	Xenetic Biosciences, Inc.
Country	United States
Country code	US
CUSIP number	984015602
Earnings date	2026-11-12
Earnings time	bmo
Employees	2
Employees change	-2
Employees growth	-50%
Enterprise value	$-1.6M
Exchange	NASDAQ
Financial currency	USD
Financial report date	2026-06-30
First seen	2026-05-09
Fiscal year end	December
Industry	Biotechnology
Is primary listing	Yes
Is SPAC	No
ISIN number	US9840156023
Last 10-K release date	2026-03-12
Last earnings date	2026-08-07
Last refreshed	2026-10-28
Last stock split date	2023-05-15
Last stock split type	Reverse
Market cap	$4.9M
Market cap category	Nano-Cap
Next earnings date	2026-11-12
Options	No
Price	$2.10
Price currency	USD
Sector	Healthcare
SIC code	2834
Stock price date	2026-10-28
Symbol	XBIO
U.S. state	Massachusetts
Website	https://www.xeneticbio.com

Valuation

Multiples, yields, enterprise-value ratios, and valuation checks.

Metric	Value
Earnings yield	-56.75%
FCF / EV yield	105.3%
FCF yield	-54.1%
P/B ratio	0.7x
P/S ratio	1.31x
Price / tangible book value	0.7x
Sector forward P/E	23.56x
Sector P/E	50.13x

Profitability

Margins, returns on capital, cash conversion, and quality metrics.

Metric	Value
EBIT margin	-81.01%
Gross margin	100%
Operating margin	-81.01%
Pretax margin	-75.91%
Profit margin	-75.91%
Profit per employee	$-1.2M
Revenue per employee	$1.6M
ROA	-26.8%
ROA (5Y)	-24.32%
ROCE	-43.5%
ROE	-47.04%
ROE (5Y)	-40.64%
ROIC	-31.38%
SBC / revenue	2.86%

Growth

Revenue, earnings, cash-flow, and forward growth indicators.

Metric	Value
EPS growth quarters	3
EPS growth years	7
Gross profit growth	33.3%
Gross profit growth (Q)	11.99%
Gross profit growth 3Y	14.75%
Gross profit growth 5Y	34.31%
Net income growth years	3
Revenue growth	33.3%
Revenue growth (Q)	11.99%
Revenue growth (QoQ)	-18.13%
Revenue growth 3Y	14.75%
Revenue growth 5Y	34.31%
Revenue growth quarters	4
Revenue growth years	1

Financial statements

Income-statement and cash-flow amounts, totals and per share.

Metric	Value
EBIT	$-2.6M
EPS	$-1.19
FCF per share	$-0.99
Financing cash flow	$4M
Free cash flow	$-2.3M
Free cash flow minus SBC	$-2.4M
Gross profit	$3.3M
Net cash flow	$1.7M
Net income	$-2.5M
Operating cash flow minus SBC	$-2.4M
Operating income	$-2.6M
Revenue	$3.3M
Stock-based compensation	$93,129

Financial strength

Debt, cash, solvency, accounting-quality, and balance-sheet signals.

Metric	Value
Altman Z-Score	-36.1
Book value per share	$2.59
Debt / equity	0
Long-term assets	$313,921
Long-term liabilities	$0
Net cash (debt)	$6.5M
Net cash / market cap	151.37%
Net cash growth	35.4%
Net debt / equity	-1.07
Piotroski F-Score	3
Shareholders' equity	$6.1M
Tangible book value	$6.1M
Tangible book value per share	$2.59
Total assets	$7M
Total cash	$6.5M
Total debt	$0
Total liabilities	$894,977
WACC	16.36%

Liquidity

Current-asset coverage and working-capital efficiency metrics.

Metric	Value
Asset turnover	0.53
Current assets	$6.7M
Current liabilities	$894,977
Current ratio	7.43
Net working capital	$-712,666
Quick ratio	7.23
Working capital	$5.8M
Working capital turnover	0.64

Dividends and buybacks

Dividend yield, payout, buybacks, and shareholder-yield indicators.

Metric	Value
Buyback yield / dilution	-34.68%
Dividend yield	0%
Shareholder yield	-34.68%

Performance and technicals

Returns, volatility, beta, momentum, RSI, and moving-average context.

Metric	Value
10Y price change	-99.61%
10Y return CAGR	-42.6%
10Y total return	-99.61%
150-day SMA	$2.96
1D price change	15.09%
1M price change	-12.13%
1M total return	-12.13%
1W price change	3.96%
1W total return	3.96%
1Y price change	-44%
1Y return CAGR	-44.02%
1Y total return	-44%
20-day SMA	$2.05
200-day SMA	$2.84
3M price change	-16%
3M total return	-16%
3Y price change	-32.74%
3Y return CAGR	-12.38%
3Y total return	-32.73%
50-day SMA	$2.90
50-day SMA vs 200-day SMA	50over200
52-week high	$4.94
52-week high date	2026-09-03
52-week low	$1.58
52-week low date	2026-10-26
5Y price change	-87.5%
5Y return CAGR	-34.03%
5Y total return	-87.5%
6M price change	-30.69%
6M total return	-30.69%
All-time high	$39,600.06
All-time high date	2014-01-31
All-time low	$1.58
All-time low date	2026-10-26
Average true range (ATR)	$0.21
Average volume	25.1K
Beta (1Y)	1.64
Beta (2Y)	0.55
Beta (5Y)	2.2
Change from 52-week high	-57.48%
Change from 52-week low	32.91%
Change from all-time high	-99.99%
Change from all-time low	32.91%
Change from open	12.9%
Day's gap	1.92%
Dollar volume	$284,661
High price	$2.10
Low price	$1.86
Monthly RSI	37.04
Open price	$1.86
Position in 52-week range	100%
Premarket change	-0.25%
Premarket close	$1.82
Premarket price	$1.82
Previous close	$1.83
Price vs 150-day SMA	-29.15%
Price vs 20-day SMA	2.54%
Price vs 200-day SMA	-26.16%
Price vs 50-day SMA	-27.61%
Relative volume	5.61
RSI	45.05
Sharpe ratio	-0.19
Sharpe ratio (3Y)	0.25
Sharpe ratio (5Y)	-0.03
Sortino ratio	-0.19
Sortino ratio (3Y)	0.56
Sortino ratio (5Y)	0.01
Volume	135.6K
Weekly RSI	42
YTD price change	-3.23%
YTD total return	-3.23%

Ownership and float

Institutional, insider, float, short-interest, and share-count fields.

Metric	Value
Float	1.9M
Float percentage	80.71%
Shares change (QoQ)	0.14%
Shares change (YoY)	34.68%
Shares held by insiders	7.99%
Shares held by institutions	1.53%
Shares outstanding	2.3M
Short % of float	0.68%
Short % of shares	0.55%
Short ratio	0.1 days

Deeper analysis on XBIO

14 sections in the full report · jump straight to what you need

Forecast

Base and Bull forecast paths with report-date return framing.

→

Valuation

Fair-value bridge, DCF, owner earnings, and peer multiples.

→

Sensitivity

Cost-of-equity and terminal-growth stress table.

→

Risks

Kill scenarios, soft-pass flags, and downside catalysts.

→

Earnings

Next earnings setup and beat / inline / miss thresholds.

→

Position sizing

Entry, exit, conviction, and quarterly monitoring rules.

→

Financials

Revenue, margins, cash flow, and balance-sheet context.

→

Peers

Relative valuation and profitability against the cohort.

→

Moat

Economic-profit evidence and competitive advantage risk.

→

Industry cycle

Sector phase, capital cycle, and secular tailwinds.

→

Frequently asked questions

About this XBIO report

Is a complete XBIO research report available?

No complete published report is available for Xenetic Biosciences, Inc. (XBIO) on this page. Market-directory data, when present, is not a substitute for a validated stock analysis.

Xenetic Biosciences, Inc. (XBIO)

Price

Financial snapshot

Fair-value bridge

Latest news · XBIO

Valuation

Profitability

Balance sheet

Trading

Next earnings

Sector percentile context

All XBIO indicators

Profile and market data

Valuation

Profitability

Growth

Financial statements

Financial strength

Liquidity

Dividends and buybacks

Performance and technicals

Ownership and float

Deeper analysis on XBIO

Frequently asked questions